Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0C3LQ
|
|||
Former ID |
DIB011550
|
|||
Drug Name |
Ulocuplumab
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 3 | [1] | |
Haematological malignancy [ICD-11: 2B33.Y] | Phase 1/2 | [2] | ||
Company |
Bristol-myers squibb
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | C-X-C chemokine receptor type 4 (CXCR4) | Target Info | Antagonist | [3], [4] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
Chemokine signaling pathway | ||||
Endocytosis | ||||
Axon guidance | ||||
Leukocyte transendothelial migration | ||||
Intestinal immune network for IgA production | ||||
Pathways in cancer | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
IL4 Signaling Pathway | ||||
Leptin Signaling Pathway | ||||
Panther Pathway | Axon guidance mediated by Slit/Robo | |||
Inflammation mediated by chemokine and cytokine signaling pathway | ||||
Pathway Interaction Database | S1P3 pathway | |||
CXCR4-mediated signaling events | ||||
Syndecan-4-mediated signaling events | ||||
HIF-1-alpha transcription factor network | ||||
Ephrin B reverse signaling | ||||
Reactome | Binding and entry of HIV virion | |||
Chemokine receptors bind chemokines | ||||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Hematopoietic Stem Cell Differentiation | ||||
HIV Life Cycle | ||||
Cardiac Progenitor Differentiation | ||||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep 1;16(9):661. | |||
REF 2 | ClinicalTrials.gov (NCT02472977) Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors. | |||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.